JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Lipopeptide Hydrogel Possesses Adjuvant-Like Properties for the Delivery of the GPC-3 Peptide-derived Antigen

  • 0Terasaki Institute for Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA 90034, USA.
Advanced Functional Materials +

|

June 13, 2025

|

June 13, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Novel lipopeptide hydrogels (LPHs) enhance peptide cancer vaccines by boosting immune responses and acting as a delivery system. These adjuvants show promise for improving vaccine efficacy against hepatocellular carcinoma (HCC).

Area Of Science

  • Biotechnology
  • Immunology
  • Materials Science

Background

  • Peptide cancer vaccines offer antigen-specific cytotoxic T lymphocyte (CTL) induction with minimal side effects.
  • Low immunogenicity and lack of dual-function adjuvants hinder clinical translation of peptide vaccines.
  • Existing adjuvants struggle to simultaneously induce cell-mediated immunity and serve as delivery systems.

Purpose Of The Study

  • To engineer a novel class of lipopeptide hydrogels (LPHs) as adjuvants for peptide-based cancer vaccines.
  • To evaluate the immune-modulating properties and delivery capabilities of LPHs.
  • To assess the potential of LPHs in enhancing vaccine efficacy against hepatocellular carcinoma (HCC).

Main Methods

  • Synthesis and characterization of lipopeptide hydrogels (Myr-FF, Myr-FFY, Cogel).
  • Loading of a glypican-3 (GPC-3) peptide targeting HCC into LPHs for sustained release.
  • In vitro assessment of LPHs as toll-like receptor (TLR)-2 agonists, costimulatory molecule upregulation, and cytokine secretion.
  • In vivo evaluation of LPHs for immune cell infiltration and toxicity.

Main Results

  • LPHs facilitated sustained release of the GPC-3 peptide over two weeks, promoting antigen uptake by antigen-presenting cells (APCs).
  • LPHs demonstrated TLR-2 agonist activity, upregulated costimulatory molecules (CD80, CD83, CD86), and induced cytokine secretion (IL-6, TNF-α).
  • In vivo studies showed increased leukocyte infiltration in lymph nodes with no observable toxicity.

Conclusions

  • Lipopeptide hydrogels (LPHs) exhibit promising adjuvant characteristics, acting as both immune modulators and delivery systems.
  • LPHs provide a novel platform for enhancing the immunogenicity and efficacy of peptide-based cancer vaccines.
  • Further investigation of LPHs is warranted for the development of advanced cancer vaccines, particularly for HCC.

Keywords: